Clinical Report: Correction to Author Affiliation Information

Overview

A correction to the original investigation on large language models for adverse-event detection in immunotherapy trials adds two institutional affiliations for Julian C. Hong, MD, MS. The notice reports an authorship-affiliation amendment and provides no new clinical or trial findings.

Background

Accurate author affiliations identify the institutions associated with published research. The correction concerns the original investigation, “Adverse Event Detection in Immunotherapy Clinical Trials Using Large Language Models,” which appeared on September 3, 2026. The supplied related notices also describe affiliation corrections in other publications, but do not provide additional findings about immunotherapy adverse-event detection.

Data Highlights

The correction notice reports no numerical or trial outcome data.

Key Findings

• The corrected article is “Adverse Event Detection in Immunotherapy Clinical Trials Using Large Language Models.”
• The original investigation appeared on September 3, 2026.
• Julian C. Hong, MD, MS, should additionally be affiliated with the Helen Diller Family Comprehensive Cancer Center at the University of California, San Francisco.
• Hong should also be affiliated with Weill Cancer Hub West at Stanford University–University of California, San Francisco.
• The notice describes an affiliation correction and does not report changes to the investigation’s methods, results, or conclusions.

Clinical Implications

The notice does not report clinical findings or changes to adverse-event detection methods. It corrects the institutional attribution for one author of the original investigation.

Conclusion

The correction adds two affiliations for Julian C. Hong to the published record. No other changes to the investigation are specified in the supplied notice.

Related Resources & Content

1. JAMA Oncology, Error in Author Affiliation, 2026 — Correction to author affiliation information
2. JAMA Network Open, Large Language Models and Adverse Event Detection Within Immunotherapy Clinical Trials, 2026 — Original investigation
3. Infection — Update: The Evolution of SARS-CoV-2: From Alpha to Omicron and Its Sublineages
4. Blood Cancer Journal — Correction Notice: Clinical Implications and Mutational Profile in Paroxysmal Nocturnal Hemoglobinuria
5. Archives of Toxicology — Correction Notice: Evaluating the Risks of Alternaria Toxins to Address Data Deficiencies and Enhance Human Health Risk Assessment
6. JAMA Oncology — Error in Author Affiliation
7. Large Language Models and Adverse Event Detection Within Immunotherapy Clinical Trials
8. Common Terminology Criteria for Adverse Events (CTCAE)
9. Therapy for Stage IV Non–Small Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, 2026.3.1 | Journal of Clinical Oncology